Company now sees 2026 net revenue of $2.85 bln to $2.89 bln
Company expects 2026 adjusted EBITDA of $490 mln to $520 mln
Company lowers 2026 outlook due to contract margin pressure and manufacturer price increase
Quarterly results miss estimates
U.S. healthcare-at-home provider's Q2 revenue grew 12.7% yr/yr but missed analyst expectations
Q2 operating income was negative and missed analyst estimates, impacted by goodwill impairment
Company recorded a $144.2 mln pre-tax goodwill write-down, which contributed to the Q2 net loss
Business drivers and portfolio changes
CAPITATED CONTRACTS - Co said new and expanded capitated agreements, including with a large national integrated delivery network and Humana OneHome, drove record volume gains and organic revenue growth
MARGIN PRESSURE - Co said transition complexity from West Coast capitated partnership and an unexpected manufacturer price increase negatively impacted margins and led to lower full-year outlook
Company agreed to sell its Diabetes Health business for $235 mln in cash to refocus its portfolio
AHCO•
